Our Services
Medical Information
Helpful Resources
Published on: 9/28/2026
Gemtesa (vibegron) treats overactive bladder by relaxing the bladder muscle, and most side effects are mild, including headache, cold-like symptoms, diarrhea, nausea, and urinary tract infection. Less common but more serious risks include urinary retention, which is more likely in people with bladder outlet obstruction or those also taking anticholinergic medications, along with rare allergic reactions such as swelling of the face, lips, or throat. Timing matters too, since some effects fade within the first few weeks while others signal a need to stop the drug, and several factors influence your personal risk. See below to understand more about which symptoms warrant a call to your doctor and which ones typically resolve on their own.
If you are unsure whether what you are feeling is a normal adjustment to Gemtesa or something that needs prompt attention, a free, instant, online symptom check can help you organize your symptoms, weigh possible causes, and understand which next steps make sense before your next appointment.
Last reviewed for medical accuracy: 09/28/2026
Gemtesa (vibegron) is a prescription medication approved to treat overactive bladder (OAB) symptoms—urgency, frequency, and urge urinary incontinence. Like any drug, Gemtesa can cause side effects. This guide reviews what to expect, how to manage common reactions, and when to speak to your doctor about serious concerns.
Gemtesa belongs to a class called β3-adrenergic agonists. It relaxes the bladder muscle (detrusor) during the storage phase, increasing bladder capacity and reducing the sudden urges to urinate that disrupt daily life and sleep.
Most side effects are mild to moderate and improve over time. In clinical trials, these were the most frequently reported:
These side effects often appear within the first few weeks and improve as your body adjusts.
While rarer, these warrant attention and may require dose adjustment or treatment discontinuation.
Gemtesa is generally well tolerated, but certain warning signs mean you should contact your healthcare provider right away:
If you experience any life-threatening or serious symptoms, seek emergency care or call your doctor immediately.
Wondering whether your symptoms are related to Gemtesa or something else? Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you sort symptoms and decide if you need to contact your provider.
free, online symptom check, using the doctor approved Ubie Symptom Checker
Always discuss any new or worsening symptoms with your healthcare provider. They can:
Keep a list of questions and bring your bladder diary to appointments. Open communication ensures you receive the safest, most effective care.
Gemtesa offers a non-anticholinergic option for managing overactive bladder, with most side effects being mild and manageable. By staying informed, tracking your experience, and seeking prompt medical advice when necessary, you can maximize benefits and minimize discomfort.
Speak to a doctor about any side effects that concern you—especially those that could be serious or life threatening. Your healthcare team is your best resource for personalized guidance.
(References)
* Frankel J, Varano S, Staskin D, Shortino D, Jankowich R, Mudd PN Jr. Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study. Int J Clin Pract. 2021 May;75(5):e13937. doi: 10.1111/ijcp.13937. Epub 2021 Jan 22. PMID: 33332699; PMCID: PMC8244055.
* He W, Huang G, Cui W, Tian Y, Sun Q, Zhao X, Zhao Y, Li D, Liu X. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023 Sep-Oct;49(5):535-563. doi: 10.1590/S1677-5538.IBJU.2023.0158. PMID: 37506033; PMCID: PMC10482468.
* Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T. Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density. PLoS One. 2023;18(9):e0290685. doi: 10.1371/journal.pone.0290685. Epub 2023 Sep 1. PMID: 37656760; PMCID: PMC10473532.
* Chastek B, Carrera A, Landis C, Snyder D, Abedinzadeh L, Bancroft T, Nesheim J, Kennelly M, Staskin D. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis. Adv Ther. 2024 May;41(5):2086-2097. doi: 10.1007/s12325-024-02824-x. Epub 2024 Mar 23. PMID: 38520502; PMCID: PMC11052770.
* Yoshimura S, Yagi H, Abe K, Yamasaki M. Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey. Low Urin Tract Symptoms. 2024 Nov;16(6):e12535. doi: 10.1111/luts.12535. PMID: 39497630; PMCID: PMC11588590.
* Woo J, Washington C, Aikin D, Colamarino RB, Worz C, Abedinzadeh L. Suitability of Crushed Vibegron 75 mg Tablets for Enteral Administration. Sr Care Pharm. 2025 Apr 1;40(4):185-193. doi: 10.4140/TCP.n.2025.185. PMID: 40134043.
* Huang W, Zheng X, Luo J, Chen Y, Xu Y. Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. Eur J Clin Pharmacol. 2025 Aug;81(8):1217-1227. doi: 10.1007/s00228-025-03855-1. Epub 2025 Jun 7. PMID: 40483336.
* Peters KM, Owens-Grillo J, Thomas E, Staskin D, Rovner ES, Mujais S. Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial. Urology. 2025 Dec;206:150-156. doi: 10.1016/j.urology.2025.08.051. Epub 2025 Sep 1. PMID: 40902908.
* He W, Wang C, Chen B, Li M, Zhang X, Cui W, Sun Q, Jiang X, Liu X. Comparative assessment of oral medications for overactive bladder in older adults: a systematic review and network meta-analysis. Aging Male. 2025 Dec 11;28(1):2568729. doi: 10.1080/13685538.2025.2568729. Epub 2025 Oct 29. PMID: 41159930.
* Yamamoto T, Yoshida S, Yajima S, Fukushima H, Yasuda Y, Waseda Y, Sato H, Hirakawa A, Honda H, Komai Y, Matsuo T, Wada N, Masuda H, Fujii Y. Efficacy of Vibegron in Overactive Bladder: A Bayesian Cross-Trial Synthesis of Benefit Probabilities and Decision Thresholds. Low Urin Tract Symptoms. 2026 Sep;18(5):e70095. doi: 10.1111/luts.70095. PMID: 42665534; PMCID: PMC13524839.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.